The evidence supporting IDO/TDO overexpression in cancer 70, 71 presents the therapeutic opportunity for tumor rejection induced by agents inhibiting IDO and/or TDO that could have clinical applications 72, 73, 74. This evidence concerns the gene IDO1 and cancer.